Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Asthma Research Group Inc., University Health Network, Toronto.
Phase
—
Status
Completed
Study type
Observational
Enrollment
152actual
Sites
1
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-17 | actual | When the study began enrolling |
| Primary completion | 2026-05-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-05 | actual | The whole study's end, after follow-up |
| First posted | 2024-07-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease (COPD)
Intervention
- Drug: Budenoside/Glycopyrronium/Formoterol
Primary outcome
what the primary-completion date above is the date OFMean change from baseline in the COPD Assessment Test (CAT) score
measured 12 weeks after treatment initiation
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed